JUBLINGREAJubilant Ingrevia Limited
Chemicals · Specialty Chemicals · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Jubilant Ingrevia Limited engages in life science products and solutions in India, the United States, Europe, China and internationally. The company operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The Specialty Chemicals segment offers bio-pyridine and -picolines, fine chemicals, agro chemicals, custom development and manufacturing services, and microbial control solutions. The Nutrition & Health Solutions segment provides nutrition and health ingredients; and animal and human nutrition health solutions. The Chemical intermediates segment offers acetyls and specialty ethanol. In addition, it provides vitamins, mineral premixes, stress regulator, amino acid, herbal choline, herbal non-antibiotic growth promoter and egg quality enhancer, toxin binder, acidifiers, and enzymes and emulsifiers. The company serves pharmaceutical, nutrition, agrochemical, consumer, and industrial sectors. The company was formerly known as Jubilant LSI Limited and changed its name to Jubilant Ingrevia Limited in October 2020. Jubilant Ingrevia Limited was incorporated in 2019 and is headquartered in Noida, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on JUBLINGREA — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 25.3% YoY
- • Profit growth: 40.6% YoY
- • Debt/Equity: 0.25
- • Golden cross setup: SMA50 above SMA200
- • 6-month return: +18.1%
- • 6-month vs NIFTY: +21.6% relative
Bull case
- • Revenue growth: 25.3% YoY
- • Profit growth: 40.6% YoY
- • Debt/Equity: 0.25
- • Golden cross setup: SMA50 above SMA200
Bear case
- • ROE: 8.9%
- • ROCE: 10.0%
- • RSI: 33
- • MACD: bearish
Key risks
- • ROE: 8.9%
- • ROCE: 10.0%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹20.19). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.